M
Melina Verso
Researcher at University of Perugia
Publications - 63
Citations - 3792
Melina Verso is an academic researcher from University of Perugia. The author has contributed to research in topics: Cancer & Deep vein. The author has an hindex of 22, co-authored 57 publications receiving 3105 citations. Previous affiliations of Melina Verso include University of Insubria.
Papers
More filters
Journal ArticleDOI
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli,Cecilia Becattini,Guy Meyer,Andrés Muñoz,Menno V. Huisman,Jean M. Connors,Alexander T. Cohen,Rupert Bauersachs,Benjamin Brenner,Adam Torbicki,Maria R Sueiro,Catherine Lambert,Gualberto Gussoni,Mauro Campanini,Andrea Fontanella,Giorgio Vescovo,Melina Verso,Caravaggio Study Investigators +17 more
TL;DR: Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding.
Journal ArticleDOI
Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients
Melina Verso,Giancarlo Agnelli +1 more
TL;DR: The recommended therapy for UL-DVT associated with CVC is based on anticoagulant therapy with or without catheter removal, and prophylaxis with low molecular weight heparin or a low fixed dose of warfarin has been recently proposed.
Journal ArticleDOI
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli,Gualberto Gussoni,Carlo Bianchini,Melina Verso,Mario Mandalà,Luigi Cavanna,Sandro Barni,Roberto Labianca,Franco Buzzi,Giovanni Scambia,Rodolfo Passalacqua,Sergio Ricci,Giampietro Gasparini,Vito Lorusso,Erminio Bonizzoni,Maurizio Tonato +15 more
TL;DR: Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy, and future studies should focus on patients who are at a high risk for thrombolic events.
Journal ArticleDOI
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
Melina Verso,Giancarlo Agnelli,Sergio Bertoglio,Franco C. Di Somma,Francesco Paoletti,Walter Ageno,Mario Bazzan,P. Parise,Roberto Quintavalla,Emanuele Naglieri,Armando Santoro,Davide Imberti,Mariella Soraru,Stefano Mosca +13 more
TL;DR: No difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo, and the dose of enoxAParin used in this study proved to be safe.
Journal ArticleDOI
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
TL;DR: A modified Khorana risk assessment score is designed by adding platinum or gemcitabine-based chemotherapy to the predictive variables already taken into account in the Khoranas, and the effect of nadroparin for VTE prophylaxis is assessed according to theKhorana and Protecht scores.